

Charlotte Gran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5300665/publications.pdf>

Version: 2024-02-01

14
papers

222
citations

1163065

8
h-index

1125717

13
g-index

15
all docs

15
docs citations

15
times ranked

451
citing authors

#	ARTICLE	IF	CITATIONS
1	Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE, 2019, 14, e0211927.	2.5	85
2	Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?. European Journal of Haematology, 2019, 103, 588-596.	2.2	24
3	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Reports Medicine, 2022, 3, 100508.	6.5	20
4	Case Report: Treatment of light chain amyloidosis with daratumumab monotherapy in two patients. European Journal of Haematology, 2018, 100, 386-388.	2.2	17
5	Outcome of COVID-19 in multiple myeloma patients in relation to treatment. European Journal of Haematology, 2020, 105, 751-754.	2.2	17
6	Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European Journal of Haematology, 2019, 103, 247-254.	2.2	11
7	Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment. European Journal of Haematology, 2020, 105, 196-202.	2.2	10
8	Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT. British Journal of Haematology, 2020, 189, e213-e217.	2.5	10
9	Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis. Acta Haematologica, 2020, 143, 500-503.	1.4	7
10	Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). American Journal of Hematology, 2021, 96, 925-933.	4.1	7
11	Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. American Journal of Hematology, 2021, 96, E63-E65.	4.1	5
12	Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. American Journal of Hematology, 2021, 96, 23-30.	4.1	5
13	Involved free light chain: an early independent predictor of response and progression in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 2227-2234.	1.3	4
14	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma – Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e206.	0.4	0